Search for Clinical Trial Results

Sponsored By

Lipid Metabolism, Inborn Errors - 15 Studies Found

Status Study
Not yet recruiting Study Name: Anti-oxLDL IgM Antibodies as a Novel Therapy for Metabolic Lipid Diseases
Condition: Lipid Metabolism, Inborn Errors
Date: 2016-01-20
Interventions: Biological: Anti-oxLDL IgM antibody Immunization
Completed Study Name: An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED)
Condition:
  • Lipid Metabolism, Inborn Errors
  • Heart Disease

Date: 2004-09-23
Interventions:
  • Drug: MK0653, ezetimibe
  • Drug: Comparator:

Completed Study Name: Sitosterolemia Extension Study (0653-004)(COMPLETED)
Condition:
  • Lipid Metabolism, Inborn Errors
  • Heart Disease

Date: 2004-09-23
Interventions:
  • Drug: MK0653, ezetimibe
  • Drug: Comparator:

Completed Study Name: Sitosterolemia Extension Study (0653-003)(COMPLETED)
Condition:
  • Lipid Metabolism, Inborn Errors
  • Heart Disease

Date: 2004-09-23
Interventions:
  • Drug: MK0653, ezetimibe
  • Drug: Comparator:

Completed Study Name: Genetic Study of Sitosterolemia
Condition:
  • Lipid Metabolism, Inborn Errors
  • Sitosterolemia

Date: 1999-10-18
Interventions: Procedure: genetic testing
Terminated Study Name: Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)
Condition:
  • Hypercholesterolemia, Familial
  • Lipid Metabolism, Inborn Errors<
    Date: 2004-09-23
    Interventions: Drug: Comparator: ezetimibe Ezetimibe (MK0653) 10 mg once daily for 3 years.
Not yet recruiting Study Name: Effects of Fish Oil and Colesevelam
Condition: Sitosterolemia
Date: 2013-09-06
Interventions:
  • Drug: Colesevelam Other Name:

Not yet recruiting Study Name: Relationship Between CETP Deficiency and Atherosclerosis in Patients With Hyperalphalipoproteinemia
Condition:
  • Low CETP Activity
  • CETP Deficiency
  • Hyperalphalipoproteinemi
    Date: 2013-07-22
Active, not recruiting Study Name: Sitosterolemia Metabolism
Condition: Sitosterolemia
Date: 2012-04-16
Interventions: Drug: Ezetimibe 10mg ezetimibe/day, at least 4 months
Completed Study Name: An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
Condition:
  • Lipid Metabolism, Inborn Errors
  • Hypercholesterolemia, Autosomal
    Date: 2008-06-05
    Interventions: Drug: Mipomersen Sodium Subcutaneous injection as a single injection directly into the abdomen, thigh, o
Next >>>